LeMaitre Vascular (LMAT) Touches $37.83 High on Sep, 11; Shorts at Zosano Pharma (ZSAN) Lowered By 0.54%

September 11, 2017 - By Michael Collier

Zosano Pharma Corporation (NASDAQ:ZSAN) had a decrease of 0.54% in short interest. ZSAN’s SI was 5.03M shares in September as released by FINRA. Its down 0.54% from 5.05 million shares previously. With 208,100 avg volume, 24 days are for Zosano Pharma Corporation (NASDAQ:ZSAN)’s short sellers to cover ZSAN’s short positions. The SI to Zosano Pharma Corporation’s float is 17.04%. About 94,416 shares traded. Zosano Pharma Corp (NASDAQ:ZSAN) has declined 31.28% since September 11, 2016 and is downtrending. It has underperformed by 47.98% the S&P500.

The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) reached all time high today, Sep, 11 and still has $40.48 target or 7.00% above today’s $37.83 share price. This indicates more upside for the $719.64M company. This technical setup was reported by Barchart.com. If the $40.48 PT is reached, the company will be worth $50.37M more. About 26,857 shares traded. LeMaitre Vascular Inc (NASDAQ:LMAT) has risen 101.07% since September 11, 2016 and is uptrending. It has outperformed by 84.37% the S&P500.

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The company has market cap of $33.80 million. The Firm has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. It currently has negative earnings. The Company’s microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Among 3 analysts covering Zosano Pharma (NASDAQ:ZSAN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Zosano Pharma had 5 analyst reports since September 29, 2015 according to SRatingsIntel. TH Capital maintained Zosano Pharma Corp (NASDAQ:ZSAN) rating on Tuesday, September 29. TH Capital has “Buy” rating and $11 target. As per Thursday, August 11, the company rating was downgraded by Ladenburg Thalmann. The stock of Zosano Pharma Corp (NASDAQ:ZSAN) has “Buy” rating given on Wednesday, November 11 by TH Capital. The firm earned “Buy” rating on Wednesday, November 11 by Roth Capital. The stock of Zosano Pharma Corp (NASDAQ:ZSAN) earned “Buy” rating by Roth Capital on Tuesday, September 29.

Among 11 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. LeMaitre Vascular had 30 analyst reports since July 29, 2015 according to SRatingsIntel. Roth Capital maintained the stock with “Buy” rating in Friday, July 28 report. The stock has “Buy” rating by TH Capital on Monday, December 7. Roth Capital maintained LeMaitre Vascular Inc (NASDAQ:LMAT) rating on Monday, December 7. Roth Capital has “Buy” rating and $18 target. The company was maintained on Friday, July 28 by Stifel Nicolaus. The firm has “Outperform” rating given on Thursday, February 25 by Barrington Research. Sidoti initiated the stock with “Neutral” rating in Wednesday, January 20 report. TH Capital maintained LeMaitre Vascular Inc (NASDAQ:LMAT) on Wednesday, July 29 with “Buy” rating. Canaccord Genuity maintained LeMaitre Vascular Inc (NASDAQ:LMAT) on Thursday, July 27 with “Hold” rating. The rating was maintained by Roth Capital with “Buy” on Tuesday, May 3. On Thursday, April 21 the stock rating was maintained by Cowen & Co with “Outperform”.

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The company has market cap of $719.64 million. The Firm develops, makes and markets medical devices and implants used primarily in the field of vascular surgery. It has a 54.42 P/E ratio. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com